39499-57-5

Upstream product

• 91266-23-8 4-oxo-4-(4-phenoxy-phenyl)-butyric acid methyl ester 
• 101-84-8 diphenylether 
• 36330-86-6 4-oxo-4-(4-phenoxyphenyl)butanoic acid 

Downstream Products

• 68394-76-3 4-furfuryl-6-(4-phenoxy-phenyl)-2H-pyridazin-3-one 
• 158502-60-4 4-(3-Chloro-benzyl)-6-(4-phenoxy-phenyl)-2H-pyridazin-3-one 
• 139286-07-0 (4-Chloro-phenyl)-(3-chloro-6-phenyl-pyridazin-4-yl)-methanone 
• 139285-97-5 4-(4-Chloro-benzoyl)-6-phenyl-2H-pyridazin-3-one 
• 158502-72-8 (3-Chloro-phenyl)-(3-chloro-6-phenyl-pyridazin-4-yl)-methanone 
• 158502-64-8 4-(3-Chloro-benzoyl)-6-phenyl-2H-pyridazin-3-one 
• 158502-67-1 4-(4-Chloro-benzoyl)-6-(4-phenoxy-phenyl)-2H-pyridazin-3-one 
• 158502-68-2 4-(3-Chloro-benzoyl)-6-(4-phenoxy-phenyl)-2H-pyridazin-3-one 
• 158502-69-3 4-(3-Bromo-benzoyl)-6-(4-phenoxy-phenyl)-2H-pyridazin-3-one 
• 68195-46-0 3-chloro-4-furfuryl-6-(4-phenoxy-phenyl)-pyridazine 
• 1105194-70-4 C₁₆H₁₁ClN₂O 
• 1027065-32-2 3-hydrazinyl-6-(4-phenoxyphenyl)pyridazine 
• 1268133-88-5 3-phenyl-6-(4'-phenoxyphenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1268133-90-9 3-(4'-tolyl)-6-(4'-phenoxyphenyl)-1,2,4-triazolo[4,3-b]pyridazine 

Relevant academic research and scientific papers

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Synthesis and in-vitro antifungal activity of 6-substituted-phenyl-2- {[(4′-substituted phenyl-5′-thioxo)-1,2,4-triazol-3-yl]-methyl}-2,3, 4,5-tetrahydropyridazin-3-one derivatives

The synthetic pathway for 6-substituted phenyl-2-[{(4′-substituted phenyl-5′-thioxo)-1,2,4-triazol-3-yl}-methyl]-2,3,4,5-tetrahydropyridazin- 3-one compounds was achieved by a sequence of reactions starting from respective aryl hydrocarbons and is illustrated in Scheme1. All the compounds were tested for their in vitro antifungal activity on five fungal species, namely Candida albicans, Trichophyton rubrum, Aspergillus flavus, Aspergillus niger and Penicillium citrinium. The chloro substituent derivative (compound 5g) showed the highest activity against all the fungal species. The MIC of the standard drug voriconazole was between 0.10 - 0.40 μg/mL against all the fungal species except A. fumigatus. The two electronegative groups of Cl were increasing the activity of 1,2,4-triazole. As we increased the bulky group or aromatic group on benzene ring, there was a decrease of activity as in case of compound l.

Synthesis and antimicrobial activity of some novel oxadiazole derivatives

A series of 5-{3′-oxo-6′-(substituted aryl)-2′,3′, 4′,5′-tetrahydropyridazin-2′-ylmethyl}-2-substituted 1,3,4-oxadiazole has been synthesized. Appropriate aromatic hydrocarbon reacts with succinic anhydride in the presence of AlCl3 to yield β-aroyl propionic acid (1a). The corresponding acid is cyclized with hydrazine hydrate to give 6-(substituted aryl)-2,3,4,5-tetrahydro-3-pyridazinone (1b).This ntermediate after reaction with ethyl bromoacetate, was hydrazinolyzed into 3-oxo-6-(substituted aryl)-2, 3, 4, 5-tetrahydropyridazinyl acetohydrazide (1c).The resulting product was converted into 5-{3′-oxo-6′-(substituted aryl)-2′,3′,4′,5′- tetrahydropyridazin-2′-ylmethyl]-2-substituted 1,3,4-oxadiazole (Scheme 1). All the final compounds were structurally elucidated on the basis of IR, 1H-NMR, MS data and elemental analysis and screened for antibacterial, antifungal and antitubercular activity. All the compounds are evaluated for their antibacterial activity against E. coli, S. aureus, Miavcoccus luteus and Klebsiella pneumoniae by using cup plate technique in the nutrient agar at 100 μg/mL concentration. Antitubercular activity was determined using the BACTEC 460 system. Stock solutions of test compounds were prepared in DMSO. MIC of rifampin was calculated by established procedures.All the synthesized compounds were screened at 6.25 μg/mL against M. tuberculosis H37 Rv comparable with that of standard rifampicin and isoniazid. All the final compounds were evaluated for antifungal activity against C. albicans and C. neoformans by using cup-plate method in the Sabouraud agar media The zone of inhibition (mm) of each compound was determined and compared with standard drug fluconazole.

Syntheses and antiinflammatory activity of some 6-aryl-2,3,4,5-tetrahydro-3-pyridazinones

6-Aryl-2, 3, 4, 5-tetrahydro-3-pyridazinones (2c-22c) are obtained by dehydrocyclisation of various hydrazides formed by the reaction of appropriate methyl β-aroylpropionate and hydrazine hydrate in the presence of anhydrous sodium acetate. They show promising antiinflammatory activity during their evaluation by carrageenin induced paw edema test in rats.

Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents

Substituted 6-phenyl-3(2H)-pyridazinone compounds are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are dehydrogenated to the desired product. The intermediate 6-phenyl-4,5-dihydro-3(2H)-pyridazinones are themselves useful as cardiotonic agents.

Pyridazinones

Compounds of the general formula: SPC1 In which X represents a straight or branched chain alkyl or alkoxy group, a hydroxymethyl group, a cycloalkyl group, a cycloalkoxy group, an aryloxy group, a hydroxyl group, a fluorine atom, a chlorine atom, an amino or substituted amino group, a piperidino group, a morpholino group, a pyrrolidino group, a 1,2,3,6-tetrahydropyridino group, a 4-[3-azabicyclo(3,2,2)-nonyl] group, or a 4-(piperazin-1-yl) or 4-(4-substituted-piperazin-1-yl) group of the formula SPC2 In which R=H, lower alkyl or 1-5 carbon atoms, aryl, substituted aryl, aralkyl, cinnamyl, acyl, ethoxy-carbonyl, aroyl or substituted aroyl and n is an integer from 1 to 5 except that when n is 1 X is not an alkyl group of 1 to 3 carbon atoms or an alkoxy group of 1 or 2 carbon atoms or a chlorine atom in the 4'-position, or an amino or acylated amino group in positions 2', 3' or 4'; and when n = 2 the groups X cannot both be methyl or both be methoxy in the 2' and 5' positions, nor can X be a chlorine atom in both the 2' and 4' positions or the 3' and 4' positions, and when n = 3, X cannot all three be methoxy. These compounds have anti-hypertensive activity.